

3. BioReference has upheld its end of the bargain and has provided the requested testing for Client. In response, however, Client has refused to pay BioReference what it is owed.

4. Because Client refuses to fulfill its payment obligations, BioReference had no choice but to bring the instant action.

THE PARTIES

5. BioReference is a limited liability company organized under the laws of Delaware, with its principal place of business at 481 Edward H. Ross Dr., Elmwood Park, New Jersey 07407-3128. BioReference is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, nursing homes, employers and governmental units. BioReference has supported New York State by providing testing for the first public drive-through testing collection facility set up on the East Coast, a model which was then replicated at dozens of other locations throughout the state. BioReference, in partnership with the State of New York, also initially offered 5,000 COVID-19 swab tests a day at additional satellite testing sites and has since increased the daily capacity significantly to address emerging needs and demand.

6. Upon information and belief, Client is a New York limited liability company with its principal place of business at 110 Beaver Dam Road, Brookhaven, NY 11719. Upon information and belief based on public filings with, *inter alia*, the New York State Department of State, Division of Corporations, the members of Bellhaven are Charles-Edouard Gros, Devorah Friedman, Sharon Einhorn, Israel Minzer, and Ernest Schlesinger, who are all citizens of the State of New York.

JURISDICTION AND VENUE

7. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332(a)(1) because there is complete diversity of citizenship and the amount in controversy, exclusive of interest and costs, exceeds \$75,000.

8. This Court has personal jurisdiction over Client pursuant to CPLR 301 because its principal places of business is in New York.

9. Venue in this District is proper pursuant to 28 U.S.C. § 1391(b)(1) and (2) because, *inter alia*, a substantial part of the events or omissions giving rise to the claims in this action occurred in this District and Client resides in this District.

FACTUAL ALLEGATIONS

Client Contracts with BioReference to Provide COVID-19 Testing

10. On May 10, 2020, amid the height of the unprecedented COVID epidemic in New York, Governor Andrew Cuomo ordered “nursing homes and all adult care facilities . . . to test or make arrangements for the testing of all personnel, including all employees, contract staff, medical staff, operators and administrators, for COVID-19, twice per week” (the “Executive Order”). The penalty for failing to comply with the Executive Order included steep fines, and in some cases, the suspension or revocation of a facility’s operating license.

11. BioReference is a provider of comprehensive testing services. Many nursing homes and laboratories contracted with BioReference to perform crucial COVID-19 testing to ensure the health and safety of nursing home residents—one of the most vulnerable populations during the pandemic. Client, a rehabilitation and nursing care center, sought BioReference’s crucial services.

12. On or around May 15, 2020, Client and BioReference¹ entered into the Agreement. A true and correct copy of the Agreement is attached hereto as Exhibit A. Pursuant to the Agreement, BioReference agreed to “perform, upon request by Client and to the extent within its capabilities, COVID-19 Tests for Tested Persons.” *See* Ex. A § 1.1.

13. The Agreement provided that “Client agrees to pay Laboratory Forty Dollars (\$40) per specimen submitted for the Serology Test performed by Laboratory, if the Laboratory’s phlebotomist performs the draw of the specimens an additional Ten Dollars (\$10) will be added to the cost of the Serology Test; and Sixty-Five Dollars (\$65.00) per specimen submitted for the RT-PCR Test performed by Laboratory.” *Id.* § 3.1. It further provided, in pertinent part, that “Laboratory shall submit a detailed written invoice to Clients in connection with COVID-19 Tests rendered under this Agreement,” *id.* § 3.2, and that “[w]ithin ten (10) days of receipt, Client shall submit payment to Laboratory for the undisputed amount of each invoice,” *id.* § 3.3.

14. The Agreement provides that “[t]he laws of the State of New Jersey shall govern the terms of this Agreement.” *See id.* § 5.11.

BioReference Performs Pursuant to the Agreement

15. Beginning in the summer of 2020, Client began sending BioReference specimens for testing, and BioReference performed the requested testing on the specimens and provided the test results to Client.

16. Client failed to submit payment to BioReference for the tests performed by BioReference pursuant to the Agreement.

¹ The Agreement was executed by BioReference Laboratories, Inc., which is the predecessor-in-interest to plaintiff BioReference Health, LLC. For ease of reference, the term “BioReference” is used throughout this Complaint.

Client Breached the Agreement by Failing to Pay Amounts Owed to BioReference

17. As detailed in the schedule appended hereto as Exhibit B, BioReference sent invoices to Client between June 2020 and March 2021 for tests performed pursuant to the Agreement.

18. BioReference billed Client \$269,897.75 pursuant to the Agreement.

19. BioReference has contacted Client multiple times concerning the outstanding payments, but Client has failed to pay.

**FIRST CLAIM FOR RELIEF
Breach of the Agreement**

20. BioReference repeats and re-alleges the allegations set forth in paragraphs 1 through 19 as if fully set forth herein.

21. BioReference and Client entered into the Agreement which is a binding and valid contract.

22. BioReference performed its obligations under the Agreement by performing the COVID-19 tests.

23. Client has failed to make payment to BioReference, in breach of the Agreement, causing BioReference injury.

24. By reason of the foregoing, BioReference is entitled to a judgment awarding it damages in an amount to be determined at trial, but not less than \$269,897.75, plus pre- and post-judgment interest.

**SECOND CLAIM FOR RELIEF
Account Stated**

25. BioReference repeats and re-alleges the allegations set forth in paragraphs 1 through 24 as if fully set forth herein.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.